Cambridge, England: Woodhead Publishing
Patent expiries of blockbuster weight loss GLP-1 (glucagon-like peptide-1) drugs are opening up a sizeable near-term opportunity for Indian pharmaceutical companies in regulated markets, led by Canada and Brazil, with a potential generic market value of about $500 million, according to Vishal Manchanda, Pharma Analyst at Systematix Group
The drug competitively inhibits muscarinic receptors, particularly peripheral M3 receptors in the gastrointestinal tract and salivary glands, thereby reducing parasympathetic cholinergic effects
The 7 Best GLP-1 Tracker Apps, Compared Ranked for the full GLP-1 journey shots, food, side effects, weight, and support with every claim checkable against a public store listing